NCT06634394 - APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

March 31, 2028

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

APVO436

Infusion drug administered as a 4 hour infusion.

DRUG

Venetoclax

Oral tablet given on days 1 through 22, of a 28 day cycle.

DRUG

Azacitidine

Intravenous infusion given on days 1-8 of a 28 day cycle

Trial Locations (7)

RECRUITING

University of Miami, Miami

RECRUITING

Gabrail Cancer Center, Canton

RECRUITING

Oncology Hematology Care, Cincinnati

RECRUITING

University of Kansas, Fairway

RECRUITING

University of Texas Southwestern Medical Center, Dallas

RECRUITING

MD Anderson Cancer Center, Houston

RECRUITING

Colorado Blood Cancer Institute, Denver